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Purpose: To compare the power of FRAX® without bone mineral density (BMD) and simpler screening tools
(OST, ORAI, OSIRIS, SCORE and age alone) in predicting fractures.
Methods: This study was a prospective, population-based study performed in Denmark comprising 3614
women aged 40–90 years, who returned a questionnaire concerning items on risk factors for osteoporosis.
Fracture risk was calculated using the different screening tools (FRAX®, OST, ORAI, OSIRIS and SCORE) for
each woman. The women were followed using the Danish National Register registering new major osteopo-
rotic fractures during 3 years, counting only the ﬁrst fracture per person. Area under the receiver operating
characteristic curve (ROC) and statistics and Harrell's index were calculated. Agreement between the tools
was calculated by kappa statistics.
Results: A total of 4% of the women experienced a new major osteoporotic fracture during the follow-up pe-
riod. There were no differences in the area under the curve (AUC) values between FRAX® and the simpler
tools; AUC values between 0.703 and 0.722 (p = 0.86). Also, Harrell's C values were very similar between
the tools. Agreement between the tools was modest.
Conclusion: During 3 years follow-up FRAX® did not perform better in the fracture risk prediction compared
with simpler tools such as OST, ORAI, OSIRIS, SCORE or age alone in a screening scenario where BMD was not
measured. These ﬁndings suggest that simpler models based on fewer risk factors, which would be easier to
use in clinical practice by the GP or the patient herself, could just as well as FRAX® be used to identify women
with increased risk of fracture.
Summary: Comparison of FRAX® and simpler screening tools (OST, ORAI, OSIRIS, SCORE) in predicting frac-
tures indicate that FRAX® did not perform better in fracture risk prediction compared with the simpler
tools or even age alone in a screening scenario without bone mineral density assessment.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. Introduction
Fragility fractures associated with osteoporosis are common [1]
and impose considerable burdens on the individual [2], increasedInstitute of Clinical Research,
ital, Kløvervænget 10, 6th ﬂoor,
Inc. Open access under CC BY-NC-SA mortality [3] and add signiﬁcant costs to the society [4]. Approxi-
mately 50% of postmenopausal women and 20% of men older than
50 years will experience a fragility fracture in their remaining lifetime
[5]. At present, the majority of men and women at high risk of
fracture are not diagnosed or treated [6] and several studies have
suggested that the case-ﬁnding strategies endorsed in many coun-
tries perform less than well [7]. Several tools have been developed
to integrate risk factors such as age, low body weight, history of frac-
tures and use of glucocorticoids into a single estimate of fracture risk
for an individual. These tools are either aimed at identifying individ-
uals with an increased risk of fractures (with the option to include a
BMD result in the risk scoring) or identifying individuals at increasedlicense. 
17K.H. Rubin et al. / Bone 56 (2013) 16–22risk of having low BMD. However, because the effect of BMD on frac-
ture risk is in itself inﬂuenced by the presence of clinical risk factors,
fracture risk tools have also been used to guide physicians in whether
to refer patients to a BMD measurement or not [8].
Fracture Risk Assessment Tool (FRAX®) uses 10 clinical risk fac-
tors and can be used with or without bone mineral density (BMD)
to predict the 10-year probability of hip fractures or major osteopo-
rotic fractures in patients (clinical spine, forearm, hip or shoulder
fracture) [9,10]. The recently updated National Osteoporosis Founda-
tion (NOF) guidelines recommend treatment of individuals with an
increased risk of fracture based on the FRAX® [11]. This involved
postmenopausal women and men aged 50 years and older with low
bone mass (T-score between−1.0 and−2.5, osteopenia) at the fem-
oral neck or spine and a 10-year hip fracture probability ≥ 3% or a
10-year major osteoporotic fracture probability ≥ 20% as calculated
by the FRAX® tool [11]. FRAX® has been validated in 11 independent
cohorts [9], and country speciﬁc adaptations are available to a large
number of countries, including Denmark [9]. Simpler approaches
have also been suggested. Age is strongly associated with fracture
risk [1] and the U.S. Preventive Services Task Force (USPSTF) recom-
mends screening with DXA in all women aged 65 years and older and
in women below 65 years with increased risk of fracture (whose
10-year fracture risk is equal to or greater than that of 65-year-old
whitewomenwithout additional risk factors; 9.3% based on FRAX® cal-
culation); diagnosis and treatment are determined from DXA result
[12]. NOF also recommends DXA testing in women above 65 years
and women aged 50–65 years with high risk factor proﬁle [11].
BMD has also a strong association with fracture risk where indi-
viduals with low BMD have progressively higher risk of fracture
[13]. Several tools based on fewer clinical risk factors are available
to predict low BMD. As discussed above, the justiﬁcation for such
tools is primarily to identify women who are more likely to have
low BMD and then could undergo BMD measurement for a deﬁnitive
assessment. The simplest tool is the Osteoporosis Self-assessment
Tool (OST), which is based on age and body weight alone [14],
while others include more risk factors in addition to age and weight:
the Osteoporosis Risk Assessment Instrument (ORAI) [15], the OSteo-
porosis Index of RISk (OSIRIS) [16], and the Simple Calculated Osteo-
porosis Risk Estimation (SCORE) [17]. All these tools have been
developed in women, validated in independent cohorts and the per-
formance of the tools was similar to that seen in the development
cohorts [15,18–20]. OST has been validated in both men [21] and
women [20,22]; validation studies of the other tools included only
women.
Since the release of FRAX® in 2008, a number of studies have com-
pared the performance of FRAX® with other online risk algorithms
with an outcome of 5 or 10-year probability of fractures and several
other parsimonious models including age. Most of these studies con-
clude that simpler models perform as well as FRAX® in predicting
fractures. Kanis et al. [23] have criticized the conclusions of these
studies in part because of the comparison of FRAX® with what
Kanis et al. called “home grown” models. Such bespoke models in-
cluded age or BMI alone, age plus BMI, age plus previous fracture.
OST, ORAI, OSIRIS and SCORE include some of the same risk factors
and they are also simpler than FRAX. However, tools will always per-
form well within the derivation cohort and the test of their perfor-
mance lies in veriﬁcation within other cohorts.
To date none has tested the performance of FRAX® compared with
the simple well validated osteoporosis risk assessment tools (ORAI,
OSIRIS, OST and SCORE) and it is uncertain whether FRAX® performs
better that these simpler tools. Therefore the aim of the present study
was to compare the power of FRAX® (without BMD) and simpler
screening tools (OST, ORAI, OSIRIS, SCORE and age alone) in
predicting fractures. We hypothesized that the more complex
FRAX® (without BMD) tool predicts fracture better than OST, ORAI,
OSIRIS, SCORE and age alone.Methods
Design
This study was a prospective, population-based study performed in
the Region of Southern Denmark. Study design and baseline data have
been reported previously [24]. In brief, data on self-reported risk factors
were collected in a random sample of the population in spring 2009.
Data regarding fractures (type and date) during follow-up were
extracted from theDanish National Patient Register (NPR) and informa-
tion on death and emigration were extracted from the Danish National
Civil Registration System (NCR) after three years of follow up.
Study population
From the NCR we randomly selected 5000 women living in the Re-
gion of Southern Denmark, aged 40–90 years, stratiﬁed by decades.
During the period from March to May 2009, a self-administered ques-
tionnaire concerning risk factors for osteoporosis was issued to the
study population together with a pre-paid return envelope. Reminders
were mailed to non-respondents twice. All women returning a ques-
tionnaire were included in the analysis, with the exception of those di-
agnosed with and treated for osteoporosis. Signed and returned
questionnaires were considered as informed consent to be included in
the analysis. All participants were anonymized and the study was ap-
proved by the Local Ethical Committee.
Questionnaire
The questionnaire was designed to enable calculation of fracture
risk based on each tool at an individual level. It therefore comprised
items on weight, height, ethnicity, history of osteoporosis, personal
and family history of fracture, smoking habits, consumption of alco-
hol, use of oral glucocorticoids, use of oestrogen, and diseases associ-
ated with secondary osteoporosis (e.g. rheumatoid arthritis, type 1
diabetes, osteogenesis imperfecta, untreated long-standing hyperthy-
roidism, hypogonadism or premature menopause (b45 years),
chronic malnutrition, or malabsorption and chronic liver disease).
The questions were constructed to allow answering by simple “yes”,
“no” or “don't know”, however, body height and weight could be en-
tered as digits. The questionnaire was validated and the reliability
tested as previously reported [24]. The questionnaire was read by op-
tical character recognition (OCR); the accuracy of this setup was pre-
viously tested without any difference in data registration [24].
Fracture risk prediction tools
Self-reported baseline data were used to calculate the 10-year
probability of fracture by FRAX® and to calculate the risk estimate
using the simpler tools, ORAI, OSIRIS, OST and SCORE in each
woman. Further, age alone was used in the analysis, where the age
of the women is used as a simple continuous variable. The number
of risk factors used in each tool varies from two in OST to 10 in
FRAX®. Table 1 shows the clinical risk factors included in each tool.
Since the detailed algorithm for FRAX® is still not in the public do-
main, the 10-year probability of fracture was calculated by individual
risk scoring using the Danish version of FRAX® [25] using a call of the
FRAX® website (version 3.4) [26]. ORAI, OSIRIS, OST and SCORE are
instruments designed to predict low BMD. The scoring system for
ORAI [15] is as follows: +2 points for non-current usage of estrogen;
+9 points for a body weight of less than 60 kg or +3 points for a
body weight between 60 and 70 kg and 0 points for weight above
70 kg; and +15 points for ages 75 years or more, +9 points for
ages between 65 and 74 years, +5 points for ages between 55 and
64, and 0 points for ages between 45 and 54. To calculate the OST
score [14], age was subtracted from weight, the result multiplied by
Table 1
Clinical risk factors included in each tool.
FRAX SCORE OSIRIS ORAI OST
Age X X X X X
Weight X X X X X
Previous low energy fractures X X X
Estrogen therapy X X X
Rheumatoid arthritis X X
Height X
Parental hip fractures X
Smoking X
Alcohol X
Glucocorticoid therapy X
Secondary osteoporosis X
Sex X
Ethnicity X
18 K.H. Rubin et al. / Bone 56 (2013) 16–220.2 and truncated to yield an integer. The OSIRIS score [16] was
calculated by adding the index valueweighted for each variable:weight
(kg) × 2 and remove last digit; age (year) × −2 and remove last digit;
+2 if a current HRT user, and −2 if the women have a history of low
impact fracture. The SCORE index [17] was calculated as: +5 points
for a race other thanblack;+4points for rheumatoid arthritis sufferers;
+4 points for non-traumatic fractures (wrist, hip and rib) over the age
of 45 years; up to a total of 12 points;+1 if the patient never used HRT,
3 times the ﬁrst digit of the patient's age, and−1 times body weight in
pounds divided by ten and truncated to an integer.
In the analyses, we primarily used the nominal score from each
tool. In analyses with tools divided into high and low risk of fractures
the following dichotomous cut-offs were used: b2 for OST, ≥6 for
SCORE, ≥9 for ORAI, ≤1 for OSIRIS, and ≥20% for FRAX® (probability
of major osteoporotic fractures). These cut-offs are based on the sug-
gestion of their developers and from validation studies of the tools in
Caucasian populations [11,15,19,22,27].
Follow-up
Incident fracture outcomes for this analysis included “major oste-
oporotic fractures” (FRAX®-deﬁned major osteoporotic fracture; hip,
clinical vertebral, wrist or humerus fracture) (ICD-10 codes: S120,
S121, S122, S220, S221, S320, T08, S422, S423, S720, S721, S722,
S525, S526), and any “osteoporotic fractures” (all fractures except
fractures of ﬁngers, toes, skull or face) (ICD-10 codes: S12, S22, S32,
S42, S52, S72, S82, T08) during the follow up period. Fracture infor-
mation on the 5000 women was collected from NPR in April 2012.
This register covers all in- and out-patient records in Danish hospitals.
Since all persons in Denmark are assigned with a unique personal
identiﬁcation number at birth, it is possible to link data from all public
registers at an individual level [28]. Records are available for any
given International Classiﬁcation of Diseases code and surgical proce-
dure [29]. The register has a high validity also regarding the diagnosis
of fractures [30,31]. Fractures during the follow-up were counted
conservatively as the ﬁrst fracture (in each category) in each person
to avoid overestimating rates due to readmissions. Hip fracture en-
tries with no appropriate surgical code associated were excluded
[32]. Follow-up information on death and emigration was also col-
lected in April 2012.
Statistical analysis
Data are shown as mean ± SD or median (range) as appropriate.
Frequency tables are used to present the prevalence of each risk fac-
tor. Chi-square test (2-sided) for categorical variables and t-test for
continued variables were applied to test the difference in baseline
characteristics of women with and without fractures during follow
up. p-values below 0.05 were considered statistically signiﬁcant.Kaplan–Meier curves of cumulative incidence of major osteopo-
rotic fractures are shown for three years of follow-up divided in
high and low risk of fractures in the different tools and age alone.
Competing risk regressions as alternative to the Kaplan–Meier curves
were conducted with incident fractures and death as failure. This
analysis was compared to the Kaplan–Meier results to assess the in-
ﬂuence of censorings not independent of occurrence of fractures.
We used receiver operating characteristic (ROC) curve analyses to
assess the ability of each tool to discriminate between womenwith or
without incident fractures. The AUC of each risk assessor for fracture
at follow-up was modeled by univariate logistic regression on the risk
assessor as only explanatory variable. In order to adjust for censored
women and take time to event (fracture) into consideration, we esti-
mated the Harrell's C index by Cox regression modeling. Harrell's C is
analog to AUC in a survival setting. Standard errors robust for cross
validation were achieved by the Jack knife-method. Tool assessors
with AUC statistics of 0.50 do not perform better than chance alone,
while tools with higher AUC statistics perform better than chance.
We compared AUC statistics between FRAX® and simpler tools
using the “roccomp” procedure in STATA. Finally, the population
was divided into quartiles based on fracture risk as predicted by
each tool and compared the observed fracture rates across the quar-
tiles. Agreement as to how well each tool assigned the women to
risk quartiles was tested using weighted kappa statistic. All analyses
were conducted using STATA 12.Results
As previously reported [24], the respondent rate to the question-
naire was 84%. A total of 334 questionnaires were blank or had several
missing items and were excluded leaving 3860 complete question-
naires. We further excluded, 246 women diagnosed with and treated
for osteoporosis, leaving 3614 women for analysis. The follow-up peri-
od ranged from March 2009 to April 2012. Mean follow up time in the
total cohort was 36 months (range 30 to 37 months) and the total
follow-up comprised 10,385 person-years. During follow-up, 156 (4%)
women suffered “major osteoporotic fractures”, 225 (6%) women
sustained an “osteoporotic fracture”, 174 women died and 6 were lost
to follow-up.
The Kaplan–Meier plots of cumulative incidence of major osteopo-
rotic fracture are shown in Fig. 1. The3 year cumulative “major osteopo-
rosis fracture” estimates for all the toolswere similar and ranged at high
risk of fracture from 8% in the FRAX® curve to approximate 6% for the
SCORE tool. Nearly identical curves were seen in competing-risks re-
gression (data not shown).
Baseline characteristics of the study population overall and strati-
ﬁed according to incident fractures are shown in Table 2. The mean
age of the women was 64 ± 13 years and mean BMI was 26 ±
5 kg/m2. Women with incident fractures were older (mean age
73 ± 11 versus 63 ± 13 years, p = 0.001), had more frequent his-
tory of fractures (22% versus 9%, p b 0.001) and history of falls dur-
ing the previous 12 months (14% versus 6%, p b 0.001), had diseases
more often related to secondary osteoporosis (26% versus 18%, p =
0.011), and had less frequently used estrogen currently (3% versus
11%, p = 0.001).
ROC curve analysis was used to assess the discrimination between
the tools. AUC values were very similar (0.703 to 0.722) with no sig-
niﬁcant differences (p = 0.86) in the AUC values between FRAX®
and the more simple tools (Table 3). Also, Harrell's C values were
very similar between the tools and identical to the AUC values of
the different tools.
Restricting the analysis to women aged 50+ years or 65+ did not
change the nonsigniﬁcant differences in the AUC values between the
tools, only the AUC values were lower; about 0.66 and 0.59, respec-
tively (data not shown).
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Fig. 1. The Kaplan–Meier plots of cumulative incidence of major osteoporotic fractures divided in high and low risk of fracture for the different tools and for age alone. *3 year frac-
ture estimates. #Division into high and low risks depends of the chosen cut-off for each tool. High risk corresponds to: FRAX® ≥ 20%, age ≥ 65 years, OSIRIS ≤ 1, OST b 2,
ORAI ≥ 9, and SCORE ≥ 6.
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quartiles of predicted risk of fractures from each tool. The tools and
age alone performed similarly (Fig. 2). The percentages of women in
the highest risk quartile who had a major osteoporotic fracture
were approximately 8% for all tools.
Agreement between the tools when assessed using weighted
kappa statistic was modest for quartiles of predicted risk of fractures
and women with incident fracture. The weighted kappa was best for
FRAX® versus age alone (0.73). It was good for FRAX® versus ORAI
(0.65) and for FRAX® versus SCORE (0.64), moderate for FRAX® ver-
sus OSIRIS (0.53) and for FRAX® versus OST (0.48).
Regarding major osteoporotic fractures, the proportion of women
in the highest risk quartile of FRAX®, who also were in the highest
quartile for other tools, was 88% for SCORE, 83% for age alone, 79%Table 2
Baseline characteristics of the 3614 women stratiﬁed according to incident major oste-
oporotic fractures.
Variable All women
N = 3614
N (%)
Fracture
N = 156
N (%)
No fracture
N = 3458
N (%)
p-value⁎
Age year, mean (SD) 64 ± 13 73 ± 11 63 ± 13 0.001
40–50 694 (19) 3 (2) 691 (20) p b 0.001
51–60 826 (23) 17 (11) 809 (23)
61–70 859 (24) 40 (26) 819 (24)
71–80 680 (19) 41 (26) 639 (19)
81–90 555 (15) 55 (35) 500 (15)
BMI kg/m2, mean (SD) 26 ± 5 25 ± 4 26 ± 5 0.07
b19 kg/m2 116 (3) 5 (3) 111 (3) 0.62
≥19 kg/m2 3498 (97) 151 (97) 3347 (97)
History of parental hip fracture 374 (10) 16 (10) 358 (10) 0.55
History of low energy fracture 337 (9) 35 (22) 302(9) p b 0.001
Smoking 742 (21) 38 (24) 704 (20) 0.14
Alcohol use, >2 drinks/day 69 (2) 2 (1) 67 (2) 0.42
Rheumatoid arthritis 175 (5) 9 (6) 166 (5) 0.34
Glucocorticoid therapy 131 (4) 7 (5) 124 (4) 0.34
Secondary osteoporosis 655 (18) 40 (26) 615 (18) 0.01
Current estrogen therapy 370 (10) 5 (3) 365 (11) 0.001
Non-black race 3604 (99.7) 156 (100) 3448 (99.7) 0.64
History of falls 218 (6) 22 (14) 196 (6) p b 0.001
⁎ p value between the group with fractured and nonfractured women.for ORAI, and 78% for both OST and OSIRIS. Restricting the analysis
to women aged 50+ years did not change the results (data not
shown).
Discussion
In this study we found that FRAX® and simpler screening tools
such as OST, ORAI, OSIRIS, SCORE and even age alone performed sim-
ilarly in predicting fractures in a screening scenario without BMD as-
sessment. The comparison between tools was based on the AUC and
the Harrell's C index by Cox regression modeling and the results
were virtually identical for all the tools.
Our results are comparable with the results of several other stud-
ies comparing FRAX® both with simple tools and more elaborate
tools [33–38]. Most of these studies have included age in the con-
struction of new models. Ensrud et al. [35] included models based
on age and BMD or fracture history in comparison with FRAX® in a
cohort study of 6652 women with 10-years of follow-up. They con-
cluded that the simple models based on age and BMD or age and frac-
ture history alone predicted the 10-year probability of fractures as
well as the more complex FRAX® model. These ﬁndings were based
on older women (mean age 71 years) and the simple model has not
yet been validated in independent populations. Bolland et al. [33]
compared age, the Garvan calculator and FRAX® in using data fromTable 3
Area under the curve for receiver operating characteristic curves for each tool and for
age alone.
3614 women Major osteoporotic fractures (N = 156) All fractures (N = 225)
AUC (95% CI) AUC (95% CI)
FRAX 0.722 (0.686, 0.758) 0.701 (0.668, 0.735)
Age alone 0.720 (0.685, 0.755) 0.694 (0.660, 0.727)
ORAI 0.713 (0.677, 0.749) 0.690 (0.658, 0.723)
SCORE 0.712 (0.675, 0.750) 0.691 (0.657, 0.725)
OST 0.704 (0.663, 0.745) 0.682 (0.646, 0.717)
OSIRIS 0.703 (0.664, 0.742) 0.681 (0.646, 0.716)
# No signiﬁcant differences in AUC values were seen between algorithms (p = 0.86 for
major osteoporotic fractures and p = 0.56 for all fractures).
*** P<0.001 in-between quartiles for each tool
Fig. 2. Observed prevalence of major osteoporotic fractures plotted according to quar-
tiles of predicted fracture risk based as estimated by FRAX®, ORAI, OSIRIS, OST, SCORE
tool and age alone. ***p b 0.001 in-between quartiles for each tool.
20 K.H. Rubin et al. / Bone 56 (2013) 16–22a RCT regarding calcium supplementation in New Zealand comprising
1422 women aged 55+ years with a follow-up period of 8.8 years.
They concluded that FRAX® and the Garvan calculator had moderate
discriminative ability for fractures and did not have greater discrimi-
nation than simpler models based on age and BMD. This study was
also based on older women (mean age 74 years). Incident fractures
were recorded by telephone interview and only 57 hip fractures oc-
curred over the 8.8 years of follow-up.
Our results are based on data without BMD using an approach
similar to that of the GLOW study [36], which comprised an interna-
tional cohort with 19,586 women aged 60+ years who had consulted
their physician in the past 24 months. They found that a simple
model consisting of age and prior fractures performed as well as
FRAX® and the Garvan calculator when BMD was unknown. As in
our study, they based assessment on self-reported clinical risk fac-
tors; however, they used self-reported incident fractures during
2 years of follow-up while we collected fracture data from national
registers. We invited participants from a random selection in the gen-
eral population and had a high responder rate (84%). In contrast, the
GLOW study group acknowledged that their sample was prone to
bias due to the selection of physicians and due to the sampling and
recruitment of patients [36]. Also, their model (with age and prior
fracture) was not validated in independent populations. Several
other studies have also compared FRAX® with other more elaborate
tools such as the QFracture algorithm [34] and the Garvan calculator
[33,37] arriving to the same conclusions as the studies mentioned
above.
In our study, agreement between the tools with regard to catego-
rizing women into quartiles of risk for major osteoporotic fracture
was moderate. However, agreement between the tools in identifying
women at the highest quartile of risk for major osteoporotic fracture
was high. Approximately 80% of the women classiﬁed in the highest
risk quartiles by FRAX® were also categorized as highest risk by all
the other tools. Sambrook et al. [36] came to a similar conclusion in
the GLOW study and our research supports that if women were se-
lected for treatment based on being in the highest quartile of risk, vir-
tually the same women would meet the threshold for treatment
regardless of the tool used.
FRAX® is the most complex tool in this study and incorporate 11
risk factors in the algorithm (and may in addition include BMD),
whereas the simpler tools only incorporated between 2 and 6 risk fac-
tors (Table 1). All the tools included age and BMI. Additional variables
did not appear to improve the performance of the tools. Both age and
BMI are associated with fracture risk, however, age is the strongestrisk factor [1]. Our study also showed that even age alone performed
as well as the FRAX® tool without BMD.
Kanis et al. [23] recently discussed potential pitfalls in external
validation of FRAX®. Several studies [33,35,38–40] compared the
AUC of ROC curves across studies. In the present study we compared
the AUC of the different predeﬁned toolswithin the same well deﬁned
study population. There are limitations to the ability of ROC analysis
to discriminate accurately between the performance of predictive
models and it is argued that addition of additional variables in models
may improve decision-making without materially increasing the AUC,
which reﬂects the diagnostic performance of the models across the
range and not just around the point at which critical decisions are
made regarding treatment [23]. Because of this, we also undertook
analyses where models were compared at relevant clinical interven-
tion threshold (Fig. 1). Kanis et al. [23] also criticized comparison of
“home grown” models with the FRAX® tool using the population
from which the “home grown” model was derived. This is a relevant
concern as the best model to ﬁt a dataset will invariably be a model
developed from that particular dataset even if the diagnostic perfor-
mance may not at all translate to other populations. In our study,
we compared the performance of FRAX® and other models to that
of age alone. This is a simple epidemiological tabulation of fracture in-
cidence as a function of age and does not constitute a bespoke model
to ﬁt the data. Furthermore, OST, ORAI, OSIRIS and SCORE are already
well validated simpler tools derived from other cohorts [15,18–20].
Another limitation accurately identiﬁed by Kanis et al. [23] is the
comparison between predicted and observed outcomes. Since we do
not have 10 years of follow-up we look at the observed fractures
and compared it with the FRAX® probability of being in risk of frac-
ture. Moreover, we took time-to-event into account by estimating
the Harrell's C which did not inﬂuence the results. Same results
were seen in the GLOW study [36]; these results also showed that
AUC values and Harrell's C values were similar for major osteoporotic
fractures. Finally, FRAX® adjusts for risk of death while the other
tools do not. Our ﬁndings, however, were robust to competing-risks
regression with both incident fractures and death as failure as alter-
native to Kaplan–Meier analysis.
In the analyses with each tool dividing participants into those with
high versus low risk of fracture we chose to use the cut-off suggested
by the developers from validation studies of tools in Caucasian popu-
lations. Different cut-offs have been also recommended even among
Caucasian populations from studies validating the tools but there
was no clear agreement regarding cut-off values for the different
tools [41–44]. One study by Rud et al. [41] investigated the perfor-
mance of SCORE, OST and ORAI in a Danish population. The sensitivity
of SCORE, OST and ORAI was 69%, 90% and 50%, respectively, when
applied as described by the developers. The authors also tried differ-
ent cut-offs with higher sensitivities, but since the study only includ-
ed peri- and early postmenopausal women (mean age 50.5 years)
and there are no other studies on Danish women conﬁrming the sug-
gested cut-off from Rud et al. [41] we found it most reasonable to use
the cut-offs from the developer of the tools in this study.
The aim of the different tools, i.e. FRAX®with OST, ORAI, OSIRIS or
SCORE, differs. FRAX® predicts the probability of fractures while
ORAI, OSIRIS, OST and SCORE are designed to predict low BMD. How-
ever, since BMD predicts fracture [45] and low BMD are strongly asso-
ciated with risk of fractures [13] the output of the simpler tools may
be perceived as a proxy for probability of fractures. Furthermore,
SCORE, OST and ORAI have once each in three different studies been
validated with fracture outcome [46–48]. The overall conclusions
from these studies were that tools to predict low BMD modestly cor-
relate with clinical fractures.
Other tools such as the Garvan calculator and the QFracture algo-
rithm have similar aim as FRAX®, but we were unable to calculate the
fracture risk of these tools since we have no data on the number of
falls but only data on whether participants have been falling more
21K.H. Rubin et al. / Bone 56 (2013) 16–22than once the last year. In our study population prior falls were signif-
icantly more frequent in fracture cases than in non-fracture cases
(14% versus 6%, p b 0,001).
Our study had a number of important strengths. First, it was a
large prospective population-based and including a wide age range
(40–90 years). Thus, the results may be applicable to the wider pop-
ulation of women. Second, we had a high response rate and 77% of the
invited population were available for analyses. Third, the question-
naire was validated in a large number of women prior to the current
study and had a high reliability [24]. Finally, the outcome data relied
on data from highly valid Danish national registers and ensured near-
ly complete follow-up [30,31]. Speciﬁcally, the diagnosis of fractures
in the NPR has previously been shown to be highly accurate [49].
Our study also has some potential limitations. Follow-up was only
three years. However, we took time-to-event into account in our
analyses and studies with longer follow-up have showed similar re-
sults [33,35,39]. We did not measure BMD in our study. This preclud-
ed the possibility to investigate the performance of FRAX® with BMD
in comparison with the simpler tools. While we cannot exclude the
possibility that FRAX® with BMD would perform better than the sim-
pler tools due to the lack of such data, other studies comparing
FRAX® with simpler models including BMD showed that FRAX®
with BMD had only a slightly higher AUC than FRAX® without BMD
and the simpler models [33,35,38,39]. A further limitation could be
that the data on clinical risk factors were self-reported and thus po-
tentially prone to bias. One study demonstrated that a cohort of post-
menopausal women over-reported their height by a mean of 2.8 cm
and underreported their weight by a mean of 2.1 kg [50]. In our
study, the use of self-reported height and weight could result in an
over-estimation of the 10-year fracture risk because the BMI might
be lower than the real BMI. Also, we cannot completely exclude the pos-
sibility that women at high risk of fractureweremoremotivated to par-
ticipate in this study. Comparison of respondents and non-respondents
revealed some differences as previously reported [24]. Finally, only
women participated in the study, thus the results are not generalizable
to men.
In conclusion our data indicate that – during medium-term
follow-up (3 years) and using self-reported clinical risk factors –
more complex tools as FRAX® did not perform better in the fracture
risk prediction compared with simpler tools such as OST, ORAI,
OSIRIS and SCORE or even age alone in a screening scenario where
BMD was not measured. These ﬁndings suggest that simpler tools
based on fewer risk factors, which would be easier to use in clinical
practice by the GP or the patient herself, could just as well as
FRAX® be used to identify women with increased risk of fracture
and therefore should be referred to a DXA scan.
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